Back

Addressing the confounding effect of dynamic drug therapy adherence in clinical trial design.

31 August 2015 (13:01 - 13:11)
Organised by:
Congress Presentation Part of: Renal denervation (RDN) for uncontrolled hypertension: introducing the SPYRAL HTN global clinical trial program Renal denervation Open Access ESC Congress 2015

About the speaker

Photo
Professor Peter Blankestijn

Utrecht (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Brief history of RDN.
Professor F. Mahfoud (Basel, CH)
Slides
Presentation thumbnail
Anatomical Optimization of renal denervation: Have we found the “sweet spot”?
Professor F. Mahfoud (Basel, CH)
Slides
Presentation thumbnail
Population variability: have we identified the correct population for renal denervation therapy?
Doctor J. Davies (London, GB)
Slides
Presentation thumbnail
Blood pressure measurement: how does the decline translate to CV risk reduction?
Professor G. Mancia (Milan, IT)
Slides
Presentation thumbnail
Introducing the SPYRAL HTN global clinical program and audience Q&A.
Professor M. Boehm (Homburg, DE)
Slides

Access the full session

Session thumbnail
Renal denervation (RDN) for uncontrolled hypertension: introducing the SPYRAL HTN global clinical trial program

The Event

Event poster

ESC Congress 2015

31 August 2015 13:01 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources